Global Recombinant Human GM-CSF for Injection Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Recombinant Human GM-CSF for Injection market size was valued at US$ 84 million in 2022. With growing demand in downstream market, the Recombinant Human GM-CSF for Injection is forecast to a readjusted size of US$ 110.3 million by 2029 with a CAGR of 3.9% during review period.
The research report highlights the growth potential of the global Recombinant Human GM-CSF for Injection market. Recombinant Human GM-CSF for Injection are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Recombinant Human GM-CSF for Injection. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Recombinant Human GM-CSF for Injection market.
Recombinant Human GM-CSF for Injection is a biopharmaceutical product that plays a critical role in stimulating the growth and function of granulocytes and macrophages, key components of the immune system. It is used to treat various medical conditions, including neutropenia, leukemia, and as an adjunct therapy for certain cancer treatments. The market for this product is substantial, driven by the rising prevalence of diseases that compromise the immune system and the development of immunotherapies. Its future development is likely to involve expanded applications in immune-related therapies, further improving patient outcomes in the treatment of various disorders.
Recombinant Human GM-CSF for Injection is a crucial biopharmaceutical product widely used in the treatment of various diseases, particularly leukemia and malignant tumors. The market for this product is substantial and continuously expanding, driven by advancements in medical technology and therapeutic approaches. In the future, it is expected that this field will continue to evolve, with specific uses of recombinant human GM-CSF potentially extending to include the treatment of more cancer types, offering further growth opportunities in the biopharmaceutical industry.
Key Features:
The report on Recombinant Human GM-CSF for Injection market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Recombinant Human GM-CSF for Injection market. It may include historical data, market segmentation by Type (e.g., 75ug, 150ug), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Recombinant Human GM-CSF for Injection market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Recombinant Human GM-CSF for Injection market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Recombinant Human GM-CSF for Injection industry. This include advancements in Recombinant Human GM-CSF for Injection technology, Recombinant Human GM-CSF for Injection new entrants, Recombinant Human GM-CSF for Injection new investment, and other innovations that are shaping the future of Recombinant Human GM-CSF for Injection.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Recombinant Human GM-CSF for Injection market. It includes factors influencing customer ' purchasing decisions, preferences for Recombinant Human GM-CSF for Injection product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Recombinant Human GM-CSF for Injection market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Recombinant Human GM-CSF for Injection market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Recombinant Human GM-CSF for Injection market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Recombinant Human GM-CSF for Injection industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Recombinant Human GM-CSF for Injection market.
Market Segmentation:
Recombinant Human GM-CSF for Injection market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Recombinant Human GM-CSF for Injection market?
What factors are driving Recombinant Human GM-CSF for Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human GM-CSF for Injection market opportunities vary by end market size?
How does Recombinant Human GM-CSF for Injection break out type, application?
According to our LPI (LP Information) latest study, the global Recombinant Human GM-CSF for Injection market size was valued at US$ 84 million in 2022. With growing demand in downstream market, the Recombinant Human GM-CSF for Injection is forecast to a readjusted size of US$ 110.3 million by 2029 with a CAGR of 3.9% during review period.
The research report highlights the growth potential of the global Recombinant Human GM-CSF for Injection market. Recombinant Human GM-CSF for Injection are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Recombinant Human GM-CSF for Injection. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Recombinant Human GM-CSF for Injection market.
Recombinant Human GM-CSF for Injection is a biopharmaceutical product that plays a critical role in stimulating the growth and function of granulocytes and macrophages, key components of the immune system. It is used to treat various medical conditions, including neutropenia, leukemia, and as an adjunct therapy for certain cancer treatments. The market for this product is substantial, driven by the rising prevalence of diseases that compromise the immune system and the development of immunotherapies. Its future development is likely to involve expanded applications in immune-related therapies, further improving patient outcomes in the treatment of various disorders.
Recombinant Human GM-CSF for Injection is a crucial biopharmaceutical product widely used in the treatment of various diseases, particularly leukemia and malignant tumors. The market for this product is substantial and continuously expanding, driven by advancements in medical technology and therapeutic approaches. In the future, it is expected that this field will continue to evolve, with specific uses of recombinant human GM-CSF potentially extending to include the treatment of more cancer types, offering further growth opportunities in the biopharmaceutical industry.
Key Features:
The report on Recombinant Human GM-CSF for Injection market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Recombinant Human GM-CSF for Injection market. It may include historical data, market segmentation by Type (e.g., 75ug, 150ug), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Recombinant Human GM-CSF for Injection market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Recombinant Human GM-CSF for Injection market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Recombinant Human GM-CSF for Injection industry. This include advancements in Recombinant Human GM-CSF for Injection technology, Recombinant Human GM-CSF for Injection new entrants, Recombinant Human GM-CSF for Injection new investment, and other innovations that are shaping the future of Recombinant Human GM-CSF for Injection.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Recombinant Human GM-CSF for Injection market. It includes factors influencing customer ' purchasing decisions, preferences for Recombinant Human GM-CSF for Injection product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Recombinant Human GM-CSF for Injection market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Recombinant Human GM-CSF for Injection market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Recombinant Human GM-CSF for Injection market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Recombinant Human GM-CSF for Injection industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Recombinant Human GM-CSF for Injection market.
Market Segmentation:
Recombinant Human GM-CSF for Injection market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- 75ug
- 150ug
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- Changchun GeneScience
- Hainan Unipul Pharmaceutical
- Harbin Pharmaceutical Group
- Guangzhou Baiyunshan Baidi Biotechnology
What is the 10-year outlook for the global Recombinant Human GM-CSF for Injection market?
What factors are driving Recombinant Human GM-CSF for Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human GM-CSF for Injection market opportunities vary by end market size?
How does Recombinant Human GM-CSF for Injection break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Country/Region, 2018, 2022 & 2029
2.2 Recombinant Human GM-CSF for Injection Segment by Type
2.2.1 75ug
2.2.2 150ug
2.3 Recombinant Human GM-CSF for Injection Sales by Type
2.3.1 Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
2.3.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Type (2018-2023)
2.3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Type (2018-2023)
2.4 Recombinant Human GM-CSF for Injection Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Recombinant Human GM-CSF for Injection Sales by Application
2.5.1 Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2018-2023)
2.5.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Application (2018-2023)
2.5.3 Global Recombinant Human GM-CSF for Injection Sale Price by Application (2018-2023)
3 GLOBAL RECOMBINANT HUMAN GM-CSF FOR INJECTION BY COMPANY
3.1 Global Recombinant Human GM-CSF for Injection Breakdown Data by Company
3.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Company (2018-2023)
3.1.2 Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2018-2023)
3.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Company (2018-2023)
3.2.1 Global Recombinant Human GM-CSF for Injection Revenue by Company (2018-2023)
3.2.2 Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2018-2023)
3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Company
3.4 Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human GM-CSF for Injection Product Location Distribution
3.4.2 Players Recombinant Human GM-CSF for Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Human GM-CSF for Injection Market Size by Geographic Region (2018-2023)
4.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Recombinant Human GM-CSF for Injection Market Size by Country/Region (2018-2023)
4.2.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Country/Region (2018-2023)
4.2.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Country/Region (2018-2023)
4.3 Americas Recombinant Human GM-CSF for Injection Sales Growth
4.4 APAC Recombinant Human GM-CSF for Injection Sales Growth
4.5 Europe Recombinant Human GM-CSF for Injection Sales Growth
4.6 Middle East & Africa Recombinant Human GM-CSF for Injection Sales Growth
5 AMERICAS
5.1 Americas Recombinant Human GM-CSF for Injection Sales by Country
5.1.1 Americas Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)
5.1.2 Americas Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)
5.2 Americas Recombinant Human GM-CSF for Injection Sales by Type
5.3 Americas Recombinant Human GM-CSF for Injection Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human GM-CSF for Injection Sales by Region
6.1.1 APAC Recombinant Human GM-CSF for Injection Sales by Region (2018-2023)
6.1.2 APAC Recombinant Human GM-CSF for Injection Revenue by Region (2018-2023)
6.2 APAC Recombinant Human GM-CSF for Injection Sales by Type
6.3 APAC Recombinant Human GM-CSF for Injection Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Human GM-CSF for Injection by Country
7.1.1 Europe Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)
7.1.2 Europe Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)
7.2 Europe Recombinant Human GM-CSF for Injection Sales by Type
7.3 Europe Recombinant Human GM-CSF for Injection Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Human GM-CSF for Injection by Country
8.1.1 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)
8.1.2 Middle East & Africa Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)
8.2 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type
8.3 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection
10.3 Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection
10.4 Industry Chain Structure of Recombinant Human GM-CSF for Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human GM-CSF for Injection Distributors
11.3 Recombinant Human GM-CSF for Injection Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION
12.1 Global Recombinant Human GM-CSF for Injection Market Size Forecast by Region
12.1.1 Global Recombinant Human GM-CSF for Injection Forecast by Region (2024-2029)
12.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Human GM-CSF for Injection Forecast by Type
12.7 Global Recombinant Human GM-CSF for Injection Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.1.3 Sanofi Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Changchun GeneScience
13.2.1 Changchun GeneScience Company Information
13.2.2 Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.2.3 Changchun GeneScience Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Changchun GeneScience Main Business Overview
13.2.5 Changchun GeneScience Latest Developments
13.3 Hainan Unipul Pharmaceutical
13.3.1 Hainan Unipul Pharmaceutical Company Information
13.3.2 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.3.3 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Hainan Unipul Pharmaceutical Main Business Overview
13.3.5 Hainan Unipul Pharmaceutical Latest Developments
13.4 Harbin Pharmaceutical Group
13.4.1 Harbin Pharmaceutical Group Company Information
13.4.2 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.4.3 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Harbin Pharmaceutical Group Main Business Overview
13.4.5 Harbin Pharmaceutical Group Latest Developments
13.5 Guangzhou Baiyunshan Baidi Biotechnology
13.5.1 Guangzhou Baiyunshan Baidi Biotechnology Company Information
13.5.2 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.5.3 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Guangzhou Baiyunshan Baidi Biotechnology Main Business Overview
13.5.5 Guangzhou Baiyunshan Baidi Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Country/Region, 2018, 2022 & 2029
2.2 Recombinant Human GM-CSF for Injection Segment by Type
2.2.1 75ug
2.2.2 150ug
2.3 Recombinant Human GM-CSF for Injection Sales by Type
2.3.1 Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
2.3.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Type (2018-2023)
2.3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Type (2018-2023)
2.4 Recombinant Human GM-CSF for Injection Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Recombinant Human GM-CSF for Injection Sales by Application
2.5.1 Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2018-2023)
2.5.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Application (2018-2023)
2.5.3 Global Recombinant Human GM-CSF for Injection Sale Price by Application (2018-2023)
3 GLOBAL RECOMBINANT HUMAN GM-CSF FOR INJECTION BY COMPANY
3.1 Global Recombinant Human GM-CSF for Injection Breakdown Data by Company
3.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Company (2018-2023)
3.1.2 Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2018-2023)
3.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Company (2018-2023)
3.2.1 Global Recombinant Human GM-CSF for Injection Revenue by Company (2018-2023)
3.2.2 Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2018-2023)
3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Company
3.4 Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human GM-CSF for Injection Product Location Distribution
3.4.2 Players Recombinant Human GM-CSF for Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Human GM-CSF for Injection Market Size by Geographic Region (2018-2023)
4.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Recombinant Human GM-CSF for Injection Market Size by Country/Region (2018-2023)
4.2.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Country/Region (2018-2023)
4.2.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Country/Region (2018-2023)
4.3 Americas Recombinant Human GM-CSF for Injection Sales Growth
4.4 APAC Recombinant Human GM-CSF for Injection Sales Growth
4.5 Europe Recombinant Human GM-CSF for Injection Sales Growth
4.6 Middle East & Africa Recombinant Human GM-CSF for Injection Sales Growth
5 AMERICAS
5.1 Americas Recombinant Human GM-CSF for Injection Sales by Country
5.1.1 Americas Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)
5.1.2 Americas Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)
5.2 Americas Recombinant Human GM-CSF for Injection Sales by Type
5.3 Americas Recombinant Human GM-CSF for Injection Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human GM-CSF for Injection Sales by Region
6.1.1 APAC Recombinant Human GM-CSF for Injection Sales by Region (2018-2023)
6.1.2 APAC Recombinant Human GM-CSF for Injection Revenue by Region (2018-2023)
6.2 APAC Recombinant Human GM-CSF for Injection Sales by Type
6.3 APAC Recombinant Human GM-CSF for Injection Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Human GM-CSF for Injection by Country
7.1.1 Europe Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)
7.1.2 Europe Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)
7.2 Europe Recombinant Human GM-CSF for Injection Sales by Type
7.3 Europe Recombinant Human GM-CSF for Injection Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Human GM-CSF for Injection by Country
8.1.1 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)
8.1.2 Middle East & Africa Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)
8.2 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type
8.3 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection
10.3 Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection
10.4 Industry Chain Structure of Recombinant Human GM-CSF for Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human GM-CSF for Injection Distributors
11.3 Recombinant Human GM-CSF for Injection Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION
12.1 Global Recombinant Human GM-CSF for Injection Market Size Forecast by Region
12.1.1 Global Recombinant Human GM-CSF for Injection Forecast by Region (2024-2029)
12.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Human GM-CSF for Injection Forecast by Type
12.7 Global Recombinant Human GM-CSF for Injection Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.1.3 Sanofi Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Changchun GeneScience
13.2.1 Changchun GeneScience Company Information
13.2.2 Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.2.3 Changchun GeneScience Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Changchun GeneScience Main Business Overview
13.2.5 Changchun GeneScience Latest Developments
13.3 Hainan Unipul Pharmaceutical
13.3.1 Hainan Unipul Pharmaceutical Company Information
13.3.2 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.3.3 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Hainan Unipul Pharmaceutical Main Business Overview
13.3.5 Hainan Unipul Pharmaceutical Latest Developments
13.4 Harbin Pharmaceutical Group
13.4.1 Harbin Pharmaceutical Group Company Information
13.4.2 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.4.3 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Harbin Pharmaceutical Group Main Business Overview
13.4.5 Harbin Pharmaceutical Group Latest Developments
13.5 Guangzhou Baiyunshan Baidi Biotechnology
13.5.1 Guangzhou Baiyunshan Baidi Biotechnology Company Information
13.5.2 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
13.5.3 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Guangzhou Baiyunshan Baidi Biotechnology Main Business Overview
13.5.5 Guangzhou Baiyunshan Baidi Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 75ug
Table 4. Major Players of 150ug
Table 5. Global Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 6. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Table 7. Global Recombinant Human GM-CSF for Injection Revenue by Type (2018-2023) & ($ million)
Table 8. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2018-2023)
Table 9. Global Recombinant Human GM-CSF for Injection Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 11. Global Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Table 12. Global Recombinant Human GM-CSF for Injection Revenue by Application (2018-2023)
Table 13. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application (2018-2023)
Table 14. Global Recombinant Human GM-CSF for Injection Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Recombinant Human GM-CSF for Injection Sales by Company (2018-2023) & (K Units)
Table 16. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2018-2023)
Table 17. Global Recombinant Human GM-CSF for Injection Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2018-2023)
Table 19. Global Recombinant Human GM-CSF for Injection Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution and Sales Area
Table 21. Players Recombinant Human GM-CSF for Injection Products Offered
Table 22. Recombinant Human GM-CSF for Injection Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Recombinant Human GM-CSF for Injection Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Recombinant Human GM-CSF for Injection Sales Market Share Geographic Region (2018-2023)
Table 27. Global Recombinant Human GM-CSF for Injection Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Recombinant Human GM-CSF for Injection Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2018-2023)
Table 31. Global Recombinant Human GM-CSF for Injection Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)
Table 34. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)
Table 35. Americas Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)
Table 37. Americas Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 38. Americas Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 39. APAC Recombinant Human GM-CSF for Injection Sales by Region (2018-2023) & (K Units)
Table 40. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Region (2018-2023)
Table 41. APAC Recombinant Human GM-CSF for Injection Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Recombinant Human GM-CSF for Injection Revenue Market Share by Region (2018-2023)
Table 43. APAC Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 44. APAC Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 45. Europe Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)
Table 46. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)
Table 47. Europe Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)
Table 49. Europe Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 50. Europe Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Recombinant Human GM-CSF for Injection
Table 58. Key Market Challenges & Risks of Recombinant Human GM-CSF for Injection
Table 59. Key Industry Trends of Recombinant Human GM-CSF for Injection
Table 60. Recombinant Human GM-CSF for Injection Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Recombinant Human GM-CSF for Injection Distributors List
Table 63. Recombinant Human GM-CSF for Injection Customer List
Table 64. Global Recombinant Human GM-CSF for Injection Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Recombinant Human GM-CSF for Injection Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Recombinant Human GM-CSF for Injection Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Recombinant Human GM-CSF for Injection Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Recombinant Human GM-CSF for Injection Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Sanofi Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 79. Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 80. Sanofi Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Sanofi Main Business
Table 82. Sanofi Latest Developments
Table 83. Changchun GeneScience Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 84. Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 85. Changchun GeneScience Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Changchun GeneScience Main Business
Table 87. Changchun GeneScience Latest Developments
Table 88. Hainan Unipul Pharmaceutical Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 89. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 90. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Hainan Unipul Pharmaceutical Main Business
Table 92. Hainan Unipul Pharmaceutical Latest Developments
Table 93. Harbin Pharmaceutical Group Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 94. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 95. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Harbin Pharmaceutical Group Main Business
Table 97. Harbin Pharmaceutical Group Latest Developments
Table 98. Guangzhou Baiyunshan Baidi Biotechnology Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 99. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 100. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Guangzhou Baiyunshan Baidi Biotechnology Main Business
Table 102. Guangzhou Baiyunshan Baidi Biotechnology Latest Developments
Table 1. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 75ug
Table 4. Major Players of 150ug
Table 5. Global Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 6. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Table 7. Global Recombinant Human GM-CSF for Injection Revenue by Type (2018-2023) & ($ million)
Table 8. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2018-2023)
Table 9. Global Recombinant Human GM-CSF for Injection Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 11. Global Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Table 12. Global Recombinant Human GM-CSF for Injection Revenue by Application (2018-2023)
Table 13. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application (2018-2023)
Table 14. Global Recombinant Human GM-CSF for Injection Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Recombinant Human GM-CSF for Injection Sales by Company (2018-2023) & (K Units)
Table 16. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2018-2023)
Table 17. Global Recombinant Human GM-CSF for Injection Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2018-2023)
Table 19. Global Recombinant Human GM-CSF for Injection Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution and Sales Area
Table 21. Players Recombinant Human GM-CSF for Injection Products Offered
Table 22. Recombinant Human GM-CSF for Injection Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Recombinant Human GM-CSF for Injection Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Recombinant Human GM-CSF for Injection Sales Market Share Geographic Region (2018-2023)
Table 27. Global Recombinant Human GM-CSF for Injection Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Recombinant Human GM-CSF for Injection Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2018-2023)
Table 31. Global Recombinant Human GM-CSF for Injection Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)
Table 34. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)
Table 35. Americas Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)
Table 37. Americas Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 38. Americas Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 39. APAC Recombinant Human GM-CSF for Injection Sales by Region (2018-2023) & (K Units)
Table 40. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Region (2018-2023)
Table 41. APAC Recombinant Human GM-CSF for Injection Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Recombinant Human GM-CSF for Injection Revenue Market Share by Region (2018-2023)
Table 43. APAC Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 44. APAC Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 45. Europe Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)
Table 46. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)
Table 47. Europe Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)
Table 49. Europe Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 50. Europe Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Recombinant Human GM-CSF for Injection
Table 58. Key Market Challenges & Risks of Recombinant Human GM-CSF for Injection
Table 59. Key Industry Trends of Recombinant Human GM-CSF for Injection
Table 60. Recombinant Human GM-CSF for Injection Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Recombinant Human GM-CSF for Injection Distributors List
Table 63. Recombinant Human GM-CSF for Injection Customer List
Table 64. Global Recombinant Human GM-CSF for Injection Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Recombinant Human GM-CSF for Injection Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Recombinant Human GM-CSF for Injection Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Recombinant Human GM-CSF for Injection Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Recombinant Human GM-CSF for Injection Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Sanofi Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 79. Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 80. Sanofi Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Sanofi Main Business
Table 82. Sanofi Latest Developments
Table 83. Changchun GeneScience Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 84. Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 85. Changchun GeneScience Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Changchun GeneScience Main Business
Table 87. Changchun GeneScience Latest Developments
Table 88. Hainan Unipul Pharmaceutical Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 89. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 90. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Hainan Unipul Pharmaceutical Main Business
Table 92. Hainan Unipul Pharmaceutical Latest Developments
Table 93. Harbin Pharmaceutical Group Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 94. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 95. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Harbin Pharmaceutical Group Main Business
Table 97. Harbin Pharmaceutical Group Latest Developments
Table 98. Guangzhou Baiyunshan Baidi Biotechnology Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
Table 99. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
Table 100. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Guangzhou Baiyunshan Baidi Biotechnology Main Business
Table 102. Guangzhou Baiyunshan Baidi Biotechnology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Recombinant Human GM-CSF for Injection
Figure 2. Recombinant Human GM-CSF for Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human GM-CSF for Injection Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Recombinant Human GM-CSF for Injection Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Recombinant Human GM-CSF for Injection Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 75ug
Figure 10. Product Picture of 150ug
Figure 11. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type in 2022
Figure 12. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2018-2023)
Figure 13. Recombinant Human GM-CSF for Injection Consumed in Hospital
Figure 14. Global Recombinant Human GM-CSF for Injection Market: Hospital (2018-2023) & (K Units)
Figure 15. Recombinant Human GM-CSF for Injection Consumed in Clinic
Figure 16. Global Recombinant Human GM-CSF for Injection Market: Clinic (2018-2023) & (K Units)
Figure 17. Recombinant Human GM-CSF for Injection Consumed in Others
Figure 18. Global Recombinant Human GM-CSF for Injection Market: Others (2018-2023) & (K Units)
Figure 19. Global Recombinant Human GM-CSF for Injection Sales Market Share by Application (2022)
Figure 20. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application in 2022
Figure 21. Recombinant Human GM-CSF for Injection Sales Market by Company in 2022 (K Units)
Figure 22. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company in 2022
Figure 23. Recombinant Human GM-CSF for Injection Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company in 2022
Figure 25. Global Recombinant Human GM-CSF for Injection Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)
Figure 28. Americas Recombinant Human GM-CSF for Injection Revenue 2018-2023 ($ Millions)
Figure 29. APAC Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)
Figure 30. APAC Recombinant Human GM-CSF for Injection Revenue 2018-2023 ($ Millions)
Figure 31. Europe Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)
Figure 32. Europe Recombinant Human GM-CSF for Injection Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue 2018-2023 ($ Millions)
Figure 35. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022
Figure 36. Americas Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022
Figure 37. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Figure 38. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Figure 39. United States Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Region in 2022
Figure 44. APAC Recombinant Human GM-CSF for Injection Revenue Market Share by Regions in 2022
Figure 45. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Figure 46. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Figure 47. China Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022
Figure 55. Europe Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022
Figure 56. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Figure 57. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Figure 58. Germany Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Figure 67. Egypt Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection in 2022
Figure 73. Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection
Figure 74. Industry Chain Structure of Recombinant Human GM-CSF for Injection
Figure 75. Channels of Distribution
Figure 76. Global Recombinant Human GM-CSF for Injection Sales Market Forecast by Region (2024-2029)
Figure 77. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Recombinant Human GM-CSF for Injection
Figure 2. Recombinant Human GM-CSF for Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human GM-CSF for Injection Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Recombinant Human GM-CSF for Injection Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Recombinant Human GM-CSF for Injection Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 75ug
Figure 10. Product Picture of 150ug
Figure 11. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type in 2022
Figure 12. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2018-2023)
Figure 13. Recombinant Human GM-CSF for Injection Consumed in Hospital
Figure 14. Global Recombinant Human GM-CSF for Injection Market: Hospital (2018-2023) & (K Units)
Figure 15. Recombinant Human GM-CSF for Injection Consumed in Clinic
Figure 16. Global Recombinant Human GM-CSF for Injection Market: Clinic (2018-2023) & (K Units)
Figure 17. Recombinant Human GM-CSF for Injection Consumed in Others
Figure 18. Global Recombinant Human GM-CSF for Injection Market: Others (2018-2023) & (K Units)
Figure 19. Global Recombinant Human GM-CSF for Injection Sales Market Share by Application (2022)
Figure 20. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application in 2022
Figure 21. Recombinant Human GM-CSF for Injection Sales Market by Company in 2022 (K Units)
Figure 22. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company in 2022
Figure 23. Recombinant Human GM-CSF for Injection Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company in 2022
Figure 25. Global Recombinant Human GM-CSF for Injection Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)
Figure 28. Americas Recombinant Human GM-CSF for Injection Revenue 2018-2023 ($ Millions)
Figure 29. APAC Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)
Figure 30. APAC Recombinant Human GM-CSF for Injection Revenue 2018-2023 ($ Millions)
Figure 31. Europe Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)
Figure 32. Europe Recombinant Human GM-CSF for Injection Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue 2018-2023 ($ Millions)
Figure 35. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022
Figure 36. Americas Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022
Figure 37. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Figure 38. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Figure 39. United States Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Region in 2022
Figure 44. APAC Recombinant Human GM-CSF for Injection Revenue Market Share by Regions in 2022
Figure 45. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Figure 46. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Figure 47. China Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022
Figure 55. Europe Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022
Figure 56. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Figure 57. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Figure 58. Germany Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
Figure 67. Egypt Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection in 2022
Figure 73. Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection
Figure 74. Industry Chain Structure of Recombinant Human GM-CSF for Injection
Figure 75. Channels of Distribution
Figure 76. Global Recombinant Human GM-CSF for Injection Sales Market Forecast by Region (2024-2029)
Figure 77. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Application (2024-2029)
